Prevalence and incidence of anal human papillomavirus infection in Mexican men: Need for universal prevention policies / Prevalencia e incidencia de infección por virus de papiloma humano en canal anal en hombres mexicanos: Necesidad de políticas de prevención universal

Abstract: Objective: Describe the natural history of anal HPV among men. Materials and methods: Prospective study among men 18-70 years (n=665), from Cuernavaca, Mexico who completed questionnaires and provided specimens (HPV genotyped) at enrollment and 1+ follow-up visit. HPV prevalence and incidence were estimated. Prevalence ratios were calculated with Poisson regression using robust variance estimation. Person-time for incident HPV infection was estimated using number of events modeled as Poisson variable for total person-months. Results: Anal infection prevalence: any HPV type=15%, high-risk=8.4%, HPV16=1.4%, tetravalent vaccine types (4vHPV)=4.4%, nonavalent vaccine types (9vHPV)=6.3%. Factors associated with prevalence: 50+ lifetime female sex partners (adjusted prevalence ratio, a PR=3.25, 95% CI:1.12-9.47), 10+ lifetime male sex partners (aPR=3.06, 95%CI:1.4-6.68), and 1+ recent male anal sex partners (aPR=2.28, 95%CI:1.15-4.5). Anal incidence rate: high-risk HPV=7.8/1 000 person-months (95%CI:6.0-10.1), HPV16=1.8/1 000 person-months (95%CI:1.1-2.9),4vHPV=3.4/1 000 person-months (95%CI:2.3-4.9) and 9vHPV=5.5/1000 person-months (95%CI:4.1-7.5). Conclusions: Implementation of universal HPV vaccination programs, including men, is a public health priority.

Resumen: Objetivo: Generar evidencia que apoye la vacunación universal contra VPH. Material y métodos: Estudio prospectivo con hombres 18-70 años (n=665) de Cuernavaca, México con cuestionarios y genotipificación de VPH en muestras (2+mediciones). Se estimó prevalencia e incidencia; se calcularon tasas de prevalencia con regresión Poisson. Se estimó persona-tiempo para infecciones incidentes. Resultados: Prevalencia de infección anal: cualquier tipo de VPH=15%, alto-riesgo=8.4%, VPH16=1.4%, tipos en vacuna tetravalente=4.4% y tipos en vacuna nonavalente=6.3%. Factores asociados con infección prevalente: 50+ parejas sexuales femeninas en la vida (tasa de prevalencia ajustada, TPa=3.25, IC95%:1.12-9.47); 10+ parejas sexuales masculinas en la vida (TPa=3.06, IC95%:1.4-6.68) y 1+ parejas masculinas (sexo anal) recientes (TPa=2.28, IC95%:1.15-4.5). Tasas de incidencia para infección anal: VPH alto-riesgo=7.8/1000 persona-meses (IC95%:6.0-10.1), VPH 16=1.8/1000 persona-meses (95%IC:1.1-2.9), tipos en vacuna tetravalente=3.4/1000 persona-meses y tipos en vacuna nonavalente=5.5/1000 persona-meses. Conclusiones: Implementación de programas de vacunación universal (incluyendo hombres) contra VPH es una prioridad en salud pública.

Anogenital warts in pediatric population

Abstract: The approach to children with anogenital warts in the context of sexual abuse is a challenge in clinical practice. This study aims to review the current knowledge of anogenital warts in children, the forms of transmission, and the association with sexual abuse and to propose a cross-sectional approach involving all medical specialties. A systematic review of the literature was conducted in Portuguese and English from January 2000 to June 2016 using the ISI Web of Knowledge and PubMed databases. Children aged 12 years or younger were included. The ethical and legal aspects were consulted in the Declaration and Convention on the Rights of Children and in the World Health Organization. Non-sexual and sexual transmission events of human papillomavirus in children have been well documented. The possibility of sexual transmission appears to be greater in children older than 4 years. In the case of anogenital warts in children younger than 4 years of age, the possibility of non-sexual transmission should be strongly considered in the absence of another sexually transmitted infection, clinical indicators, or history of sexual abuse. The importance of human papillomavirus genotyping in the evaluation of sexual abuse is controversial. A detailed medical history and physical examination of both the child and caregivers are critical during the course of the investigation. The likelihood of an association between human papillomavirus infection and sexual abuse increases directly with age. A multidisciplinary clinical approach improves the ability to identify sexual abuse in children with anogenital warts.

Human papillomavirus vaccine efficacy in the prevention of anogenital warts: systematic review and meta-analysis / Eficacia de la vacuna contra el virus del papiloma humano en la prevención de verrugas anogenitales: revisión sistemática y metanálisis

Abstract: Objective: To review evidence on the efficacy of HPV vaccines in the prevention of non-cancer lesions (anogenital warts [AGW], recurrent laryngeal papillomatosis and oral papillomatosis). Materials and methods: We conducted a systematic review of randomized trials. We performed random effect models and effects were reported as relative risks (RR) and their confidence intervals (95%CI) following both intention to treat (ITT) and per protocol (PP) analyses. Results: We included six studies (n=27 078). One study was rated as high risk of bias. One study could not be included in the meta-analysis because it provided combined results. We found that quadrivalent vaccine reduced the risk of AGW by 62% (RR: 0.38, 95%CI:0.32-0.45, I2:0%) in the ITT analysis and by 95% (RR: 0.05, 95%CI:0.01-0.25, I2:66%) in the PP analysis. Subgroup analyses of studies in women or with low-risk of bias provided similar results. Conclusion: HPV quadrivalent vaccine is efficacious in preventing AGW in men and women.

Resumen: Objetivo: Revisar la evidencia sobre la eficacia de las vacunas contra el virus del papiloma humano en la prevención de lesiones no oncológicas (verrugas anogenitales [VAG], papilomatosis recurrente respiratoria y papilomatosis oral). Material y métodos: Realizamos una revisión sistemática de ensayos clínicos aleatorizados. Empleamos modelos de efectos aleatorios, calculando riesgos relativos (RR) y sus intervalos de confianza al 95% (IC95%), utilizando el análisis por intención a tratar (ITT) y por protocolo (PP). Resultados: Seleccionamos seis estudios (n=27 078). Un estudio tuvo alto riesgo de sesgo y otro no fue incluido en el metanálisis. La vacuna cuadrivalente reduce el riesgo de VAG en 62% (RR: 0,38; IC95%:0,32-0,45; I2:0%) en el análisis ITT y en 95% (RR: 0,05; IC95%:0,01-0,25; I2:66%) en el análisis PP. Los análisis de subgrupos (mujeres y estudios con bajo riesgo de sesgo) proporcionaron resultados similares. Conclusión. La vacuna cuadrivalente es eficaz en la prevención de VAG en hombres y mujeres.

Prevalência da lesão HPV induzida em canal anal de mulheres com neoplasia intraepitelial cervical 2 e 3: um estudo de corte transversal / Prevalence of HPV-induced lesions in the anal canal among women with cervical intraepithelial neoplasia 2 and 3: cross-sectional study

OBJETIVO: Determinar a prevalência da lesão anal induzida por HPV em mulheres com neoplasia intraepitelial cervical grau 2/3 (NIC2/3).MÉTODOS: Estudo transversal, realizado no período de dezembro de 2008 a junho de 2009, no Estado de Pernambuco, nordeste do Brasil. Foram incluídas no estudo apenas mulheres com diagnóstico de NIC2/3 confirmado por biópsia e excluídas aquelas que não realizaram exame na primeira visita. As amostras para identificação do DNA de HPV anal por PCR e citologia anal foram coletadas com escovinha endocervical. A biópsia anal foi realizada nos casos de citologia anal anormal ou alterações maiores na anuscopia de alta resolução (AAR).RESULTADOS: Das AARs, 32,1% (n=37/115) foram normais e 63,5% (n=73/115) exibiram epitélio acetobranco. Vinte e dois por cento das citologias anais (n=26/115) foram anormais. Dentre elas, 12,2% (14/26) corresponderam à lesão intraepitelial anal de baixo grau e 3,4% (n=4/26), a lesão intraepitelial anal de alto grau. Foram realizadas 22 biópsias, das quais 13,7% (n=3/22) tiveram diagnóstico de neoplasia intraepitelial anal (NIA2) e 9% (n=2/22), NIA 3. Identificou-se 72,1% (n=83/115) de DNA do HPV nas amostras.CONCLUSÃO: Mulheres com NIC2/3 apresentam elevada prevalência de infecção por HPV e lesão HPV induzida em canal anal.

PURPOSE: To determine the prevalence of HPV-induced lesions in the anal canal of women with cervical intraepithelial neoplasia (CIN) grade 2/3.METHODS: A cross-sectional study was carried out from December 2008 to June 2009, in Pernambuco, northeastern Brazil. Only women with grade 2/3 CIN were included, and those who could not undergo anoscopy during their first visit were excluded. A cyttobrush was used for sample collection in order to identify HPV DNA through PCR and anal cytology. An anal biopsy was obtained in cases of abnormal anal cytology or major alterations in high resolution anoscopy (HRA).RESULTS: Thirty-two percent (n=37/115) of HRA were normal and 63.5% (n=73/115) showed acetowhite epithelium. Twenty-two percent (n=26/115) of anal cytologies were abnormal. Among the latter, 12.2% (n=14/26) were low-grade anal intraepithelial lesions and 3.4% (n=4/26) were high-grade anal intraepithelial lesions. Twenty-two anal biopsies were performed, 13.7% of which (n=3/22) were grade 2 anal intraepithelial neoplasia (AIN2) and 9% (n=2/22) were grade 3 AIN. Th HPV DNA was identified in 72.1% of cases (n=83/115).CONCLUSION: Women with CIN grade 2/3 showed a high prevalence of anal HPV infection and HPV-induced lesions.

Detección temprana de la displasia anal con citología (PAP) y anoscopía de alta resolución (AAR) en la población de riesgo: experiencia inicial / Early detection of anal dysplasia with cytology (PAP) and high resolution anoscopy (AAR) in the population at risk: initial experience

Antecedentes: La incidencia del carcinoma de células escamosas anal (CCE) aumentó drásticamente, es de 35/100.000 habitantes en los hombres que tienen sexo con hombres (HSH), similar a la del cáncer del cuello uterino antes del Papanicolaou (PAP). En forma análoga a la pesquisa del cáncer cervical, el PAP anal y la anoscopía de alta resolución (AAR), se utilizan para la detección temprana de las lesiones precursoras del CCE. Objetivo: Evaluar los hallazgos de la citología anal y la AAR en una población de alto riesgo para desarrollar displasia y CCE. Diseño: Observacional, descriptivo, transversal, prospectivo. Población: Pacientes de alto riesgo (individuos HIV positivos, hombres que tienen sexo con hombres (HSH), mujeres con antecedentes de cáncer o displasia del tracto genital inferior, individuos con antecedentes de HPV anal o genital) que concurrieron al Consultorio de Detección Temprana de la Displasia Anal, entre 1 abril y 30 junio 2012. Método: Tacto rectal, anoscopía convencional, PAP anal y AAR, con biopsia dirigida de lesiones sospechosas. Comparación de la citología con la histología...

Background: The incidence of anal squamous cell carcinoma (SCC) has increased dramatically, with an incidence of 35/100.000 inhabitants in men who have sex with men (MSM), similar to that of cervical cancer before the Papanicolaou (PAP). In analogy form to screening of cervical cancer, anal PAP and high resolution anoscopy (HRA) are used for early detection of SSC precursor lesions. Objective: To assess the findings of anal cytology and HRA in a high risk population for developing dysplasia and SCC. Design: Cross-sectional, descriptive, prospective, study. Population: High-risk patients (HIV- positive individuals, men who have sex with men, women with previous cancer or dysplasia of the lower genital tract, individuals with previous anal or genital condylomata) who attended the Anal Dysplasia Early Detection Clinic between April 1-June 30, 2012, were included. Methods: Digital rectal examination, conventional anoscopy, anal PAP and HRA, with biopsies of suspected areas was performed...

Prevalencia de patología ano-rectal en pacientes portadores de VIH/SIDA / Prevalence of ano-rectal pathology in HIV/AIDS patients

Introduction: The ano-rectal pathology (ARP) is the most common surgical condition in patients with human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS). Our aim was to determine the current prevalence and clinical characteristics of the ARP in patients with HIV/AIDS in clinical control in the infectious diseases unit of the Hernán Henríquez Aravena Hospital in Temuco. Patients and Method: Study design: Cross section. Location and period: Infectious Diseases Unit of the hospital during the month of June 2010. Inclusion criteria: Patients with HIV/AIDS under control in the unit, medical records were analyzed and complete physical examination was performed. Results: In the period of study 384 patients were in control in the unit. Fifty had ARP which is a prevalence of 13%. Anal condyloma disease and hemorrhoidal disease were the most common diseases. Most patients (76%) were on antiretroviral therapy with good clinical response. Conclusion: The prevalence of ARP in HIV/AIDS patient has increased in recent years. This study shows a change in the pattern of presentation, being anal condyloma the most common ARP.

Introducción: La patología ano-rectal (PAR) es la afección quirúrgica más frecuente en pacientes portadores del virus de la inmunodeficiencia adquirida (VIH) y del síndrome de la inmunodeficiencia adquirida (SIDA). Nuestro objetivo fue determinar la prevalencia actual y las características clínicas de la PAR en pacientes portadores de VIH/SIDA en control clínico en la unidad de infectología del Hospital Doctor Hernán Henríquez Aravena de Temuco. Materiales y Método: Diseño de estudio: Corte transversal. Lugar y período: Unidad de Infectología del Hospital Doctor Hernán Henríquez Aravena de Temuco durante el mes de junio de 2010. Criterios de inclusión: Pacientes portadores de VIH-SIDA en control en la unidad, se analizó su historial clínico y se realizó un examen físico completo. Resultados: Durante el período 384 pacientes se encontraban en control en la unidad. Cincuenta presentaron PAR lo que constituye una prevalencia del 13%. La condilomatosis anal y la enfermedad hemorroidal fueron las patologías más frecuentes. La mayoría de los pacientes (76%) se encontraban en terapia anti-retroviral y con buena respuesta clínica. Conclusión: La prevalencia de patología ano-rectal en pacientes portadores de VIH/ SIDA se ha incrementado en los últimos años. Se aprecia un cambio en las características clínicas de presentación, siendo la condilomatosis anal la PAR más frecuente.

Diagnóstico de HPV anal em mulheres com NIC: prevenção de câncer do ânus? / Anal HPV diagnosis in women with NIC: anal cancer prevention?

Os objetivos deste estudo foram avaliar a frequência de HPV anal em pacientes com neoplasia intraepitelial cervical (NIC), verificar a concordância entre os subtipos encontrados nos dois locais e investigar os fatores que influenciaram a ocorrência de HPV anal em mulheres com NIC sem evidências clínicas de imunodepressão. Foram avaliadas 52 mulheres com idades entre 16 e 72 anos e diagnóstico de neoplasia intraepitelial cervical graus I, II e III. A identificação do DNA (ácido desoxirribonucleico) do HPV e de sete subtipos dos vírus foi realizada por meio da reação em cadeia da polimerase (PCR) em material colhido no ânus e colo uterino. Foram pesquisados fatores que poderiam contribuir para a infecção anal, como paridade, número de parceiros, tabagismo, manipulação e coito anal e o tipo de doença ginecológica. Das 52 mulheres, foi diagnosticado HPV na região anal em 25 (48 por cento), das quais 23 (44 por cento) também apresentavam HPV no colo uterino - resultado significativo para existência do HPV em portadoras de NIC. Em 16 (31 por cento) o HPV foi diagnosticado somente no colo uterino e em 11 (21 por cento) não foi identificado em colo ou ânus. Houve associação significativa nas variáveis paridade (p=0,02) e número de parceiros (p=0,04). Concluiu-se que: as mulheres com HPV genital têm mais probabilidade de serem acometidas por HPV anal; não há concordância unânime entre os subtipos do HPV do colo do útero e do ânus e a paridade e o número de parceiros contribuem para aumentar a incidência de HPV anal nas mulheres sem imunodeficiência e com HPV cervical.

This study aims were to assess the frequency of HPV anal infection in patients with cervical intra-epithelial neoplasia (CIN), to find out the relation between the found subtypes, when present in both regions, and investigate factors that influenced the occurrence of anal HPV in women with CIN. Fifty two women with age between 16 and 72 years and cervical intra-epithelial neoplasia (CIN) diagnosis, grades I, II and III were studied. Material from anus and uterine cervix were obtained to identify the virus deoxyribonucleic acid (DNA) and seven virus subtypes through polymerase chain reaction (PCR). Factors that could contribute to anal infection like number of children, number of sexual partners, smoking practice, anal manipulation and intercourse, and grade of gynecologic disease were investigate. From the fifty two women, anal HPV diagnoses happened in 25 (48 percent), and 23 (44 percent) of them had HPV in uterine cervix as well; this result was significant to the presence of anal HPV in patients with CIN. In 16 (31 percent) the HPV diagnosis occurred only in uterine cervix and in 11 (21 percent) no HPV was detected in anus and uterine cervix. In conclusion, women with cervical intra-epihelial neoplasia have more probability to be infected with anal HPV; there is no unanimous concordance among HPV sub-types in uterine cervix and anus and the number of children and sexual partners contribute to increase the anal infection incidence in women without immuno-deficiency, with cervical HPV infection.

Diagnostic methods for prevention of anal cancer and characteristics of anal lesions caused by HPV in men with HIV/AIDS

Abnormalities found with anuscopy under colposcopic vision, anal cytology and anal biopsy were evaluated in 21 men with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) at the Federal University of Pernambuco Hospital in Brazil. Mean age was 38.4 ± 6.0 years, and mean time of HIV infection was 8.3 ± 5.1 years; 95.2 percent of the patients had been on highly active antiretroviral therapy (HAART) for an average of 6.6 ± 4.5 years. Mean CD4+ cell count was 482.2 ± 173.75 cells/mm³, and 80.9 percent presented a HIV viral load of < 5,000 copies/mL. Reported sexual preference was 52.4 percent homosexuals, 28.6 percent bisexuals, and 19.0 percentheterosexuals; 81 percent reported having had receptive anal intercourse and 61.9 percent reported more than 10 sexual partners of the same sex. Results of anuscopy under colposcopic vision revealed 17 (81.0 percent) low-grade lesions and/or condylomata or micropapillae and four (19.0 percent) high-grade lesions with or without condylomata. Among the 21 anal cytology examinations, seven (33.3 percent) revealed low-grade squamous intraepithelial lesions (LSIL); three (14.3 percent) presented atypical squamous cells of undetermined significance (ASCUS) and 11 (52.4 percent) were normal. Seventeen patients were submitted to anal biopsy with the following findings: three patients (17.6 percent) with normal epithelium, one (5.9 percent) with infection by HPV, three (17.6 percent) with condylomatas, two (11.8 percent) with AIN 1, four (23.6 percent) with AIN 2, three (17.6 percent) with AIN 3, and one (5.9 percent) with PAIN 2. Anuscopy under colposcopic vision was found to be useful for detecting anal lesions and for guiding anal biopsies. Anal cytology was less useful, as it underestimated the frequency of lesions.

HPV perianal en pacientes HIV positivos: anoscopía magnificada y determinación de serotipos por biología molecular / Perianal HPV in HIV patients: high resolution anoscopy and virus type determination by molecular biology

Introducción: La incidencia de cáncer anal se ha incrementado notablemente en los últimos años. La asociación de esta patología con la presencia de infección anal por el virus HPV permite identificar una población de riesgo, principalmente en pacientes con serología positiva para HIV y con prácticas homosexuales. Objetivo: Determinar la incidencia de lesiones perianales clínicas y subclínicas vinculables a la infección por HPV (virus del papiloma humano) en una población de individuos infectados por HIV (virus de la inmunodeficiencia humana). Material y Método: Entre el 1 de Noviembre de 2006 y 31 de Junio de 2007 se analizaron prospectivamente 33 pacientes con diagnóstico de HIV, 60 por ciento sexo femenino, edad media de 40 años (r = 19-62). Las variables en estudio fueron edad, sexo, recuento de CD4, nadir de CD4, carga viral, antecedentes de HPV previo, hábito sexual, tratamiento antirretroviral, HIV status, antecedentes de ETS (Enfermedades de transmisión sexual), inspección y anoscopía, anoscopía magnificada, citología, biopsia, serotipo de riesgo, tratamiento. Resultados: Los resultados genéticos confirmaron 54.5 por ciento (18) casos de infección; correspondiendo 77.7 por ciento a cepas de bajo riesgo y 22.2 por ciento a cepas de alto riesgo. La inspección y anoscopía simple mostró lesión sospechosa de HPV en 30 por ciento de los pacientes y la anoscopía magnificada en el 45 por ciento de los pacientes. La citología mostró lesión sugestiva de HPV en 36.3 por ciento y atipía citológica en 27.2 por ciento. Las biopsias revelaron 27.2 por ciento de lesiones típicas de condiloma, 18.2 por ciento de lesiones AIN (neoplasia intraepitelial anal) y 3 por ciento de hiperparaqueratosis. La sensibilidad y especificidad para la inspección, anoscopía magnificada y cepillado fue de 44.4 por ciento, 72 por ciento y 77 por ciento; y de 86 por ciento, y 53.3 por ciento respectivamente...

Background: The incidence of anal cancer has increased in the last years. The association between anal cancer and HPV anal infection let us identify a risk population, principally HIV patients with men sexual men practices. Aim: To asses the incidence of anal and perianal lesions associated with HPV (human papillomavirus) infection in HIV (human immunodeficiency virus) positive patients. Material and Methods: Between 1 November 2006, to 31 June 2007, 33 patients with positive serology for HIV infection were prospectively analyzed, 60 per cent females, median age 40 years (r = 19-62). The variables included in the study were age, gender, CD4 recount, CD4 nadir, viral charge, HPV previous history, sexual habits, type of retroviral treatment, HIV status, sexually transmitted disease history, simple anoscopy, high resolution anoscopy, pap cytology, pathology results, viral HPV type, treatment. Results: Genetic reports informed 54,5 per cent (18) of positive HPV patients, 77,7 per cent low risk viral type and 22 per cent of high risk. Inspection and conventional anoscopy showed 30 per cent of suspicious HPV lesions and high resolution anoscopy 45 per cent of them. Citology report informed 36,3 per cent of cellular changes associated with HPV infections and 27,2 per cent of atypia. The pathology report confirmed 27,2 per cent of typical HPV warms, 18,2 per cent of AIN (anal intraepithelial neoplasia) and 3 per cent of ASCUS (anal squamous cells of uncertain significance). Inspection and conventional anoscopy, high resolution anoscopy and citology by anal brushing showed sensibility and specificity of 44,4 per cent, 72 per cent and 77 per cent and 86 per cent, 86 per cent, 53,3 per cent respectively. Conclusions: HPV anal and perianal infection in HIV patients is frequent independently of sexual habits. High resolution Anoscopy and molecular diagnostic with viral type determination allow us to find sub clinical lesions of risk.

Imiquimod en crema al 5% en el tratamiento de verrugas anogenitales asociadas a VPH: experiencia preliminar / Imiquimod 5% cream in the treatment of anogenital warts HPV associated

Antecedentes: La infección persistente por VPH de alto riesgo se asocia con cáncer cervicouterino, encontrándosepositividad en el 99,7% de los casos. Las verrugas anogenitales son una forma de presentación de la infección persistente. Objetivo: Investigar la eficacia y seguridad de imiquimod en crema al 5%, en el tratamiento de las verrugas anogenitales en mujeres. Método: Estudio prospectivo no randomizado, en mujeres portadoras de verrugas anogenitales asociadas a VPH. El tratamiento consiste en la autoaplicación de imiquiomod en crema al 5% tres veces a la semana por hasta un período de 16 semanas. Se define como respuesta completa al tratamiento aquella en que desaparece completamente la lesión; por respuesta parcial la disminución de al menos un 50% del volumen inicial de la lesión. Resultados: Durante un período de 8 meses fueron ingresadas y tratadas 38 pacientes La duración del tratamiento varió entre 1 y 4 meses. El número promedio de aplicaciones fue de 28,7. El 66% (25 casos) de las pacientes presentaron una respuesta completa, en tres casos no hubo respuesta, uno de ellos en una paciente inmunodeprimida, en 10 casos hubo respuestas parciales. En las pacientes con respuestas completas se necesitó un promedio de 28,7 aplicaciones hasta obtener el resultado. Conclusiones: Imiquimod es un fármaco con buena efectividad y seguridad en el tratamiento de las verrugas anogenitales asociadas a VPH, en tratamiento de tres veces por semana durante mínimo de 10 semanas.

Background: The chronic infection by high-risk HPV serotypes is strongly associated with cervical cancer, detection of HPV on tissue sample has been reported 99.7% of cases. The anal-genital warts represent the clinical manifestation of the persistent infection by this virus. Objectives: To investigate the efficacy and safety of Imiquimod cream 5% concentration, in the treatment of anal-genital warts in women. Methods: A non-randomized prospective study in women diagnosed with anal-genital warts HPV associated. The treatment consists in self-application of imiquimod cream 5%, three times a week for a period of 16 weeks or more. We define complete response to treatment in those patients where the lesion disappeared completely, and partial response to those where the lesion declined at least 50% of its initial volume. Results: Over a period of 8 months were admitted to the study and treated a total of 38 patients. Treatment duration varied between 1 and 4 months. The average number of applications was 28.7 times. 66% (25 cases) of the patients had a complete response, in three cases there was no response, one of them was an immunodepressed patients, in 10 cases there was partial response. The patients with complete response needed an average of 28.7 applications to get that result. Conclusions: Imiquimod is a drug with high effectiveness and safety in the treatment of anal-genital warts HPV associated, in a three times per week and at least 10 weeks total duration treatment.

Tratamiento quirúrgico de condilomas perianales en pacientes VIH positivos / Surgical treatment of anogenital warts in hiv positive patients

Los condilomas acuminados corresponden a la patología ano rectal más frecuente en los pacientes portadores del virus de la inmuno deficiencia humana (VIH+). Su tratamiento genera controversias por la posible progresión a carcinoma epidermoide y su alta recurrencia. Se presenta nuestra experiencia en el tratamiento de los condilomas acuminados en pacientes VIH+. La serie corresponde a veinte pacientes todos homosexuales de sexo masculino, con edad promedio de 32 años, once de ellos recibían terapia anti retroviral al momento de la cirugía. Los síntomas más frecuentes fueron el sangrado, el prurito y la sensación de masa anal. Quince pacientes presentaron condilomas en todo el margen anal con extensión al canal anal. En cuatro casos se realizó fulguración de las lesiones y los restantes fueron resecados. La anatomía patológica de estos casos mostró infección por virus papiloma en todos ellos, con displasia moderada en solo un caso. No se registraron casos de displasia intensa ni carcinoma invasor. El seguimiento alejado se logró en 16 pacientes, dos de ellos presentaron recidiva de las lesiones debiendo ser sometidos a un nuevo procedimiento quirúrgico sin nuevas recidivas y lográndose el control sintomático en todos ellos. Los cuatro pacientes restantes se encuentran fallecidos por su patología de base. En esta serie aunque la histología no muestra displasia intensa ni carcinoma, el control sintomático justifica el tratamiento quirúrgico de estas lesiones.

Tumor de Buschke-Lowenstein malignizado / Malignant Buschke-Lowenstein tumor

El condiloma acuminado gigante fue descrito originalmente por Buschke y Lowenstein en 1925, como una lesión del pene; con menor frecuencia ha sido encontrado en la región anorrectal, habiéndosele informado de franca transformación maligna en carcinoma epidemoídeo. Se describen dos casos clínicos de condiloma acuminado gigante malignizado del periné. Ambos fueron sometidos a resección radical de la lesión. Estas lesiones son propensas a recidivar, por lo que se recomienda una resección extensa acompañada de buen seguimiento postoperatorio, lo que otorga mejor pronóstico